Medical  Explorer

Custom Search

Drugs A to Z  :  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  R  S  T  U  V  W  X  Y  Z
Medicinal Ingredients : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Beauty Products : A  B  C  D  E  F  G  I  M  N  O  P  R  S  T  V

Aging      Allergies     Alzheimer's      Arthritis    Asthma      Bacteria   new Cancer    Chickenpox     Colds     Constipation      Diabetes      Epilepsy     Fatigue     Fever     Genetics       Haemorrhoids       newHeadaches      Hepatitis    Immunity      Infection      Insomnia       Leprosy       Menopause      Obesity      Osteoporosis     Other Diseases    Pain      PMS     Parasites     Sinusitis     newStroke     Toxicology    Urology




Arthritis medications
Acupuncture
Alcohol
Patients
newGeneral Health
Medicinal food
Chinese medicine
Nutrients
Smoking
Vitamins
OTC Drugs
Health Products
Therapy
Symptom
Parasitology
 
 

Zopim F.C.

 

INGREDIENT
Each tablet contains:
Zolpidem Hemitartrate .................10 mg

DESCRIPTION
It is a -.white, oblong, biconvex tablet, a S|T is scored on the one side and 385 on the other side.

CLINICAL PHARMACOLOGY
Pharmacodynamics
Subunit modulation of the GABAa receptor chloride channel macromolecular complex is hypothesized to be responsible for sedative, anticonvulsant, anxiolytic, and myorelaxant drug properties. The major modulatory site of the GABAa receptor complex is located on its alpha subunit and is referred to as the benzodiazepine (BZ) or receptor. At least three subtypes of the receptor have been identified.

While zolpidem is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines. In contrast to the benzodiazepines, which non-selectively bind to and activate all three omega receptor subtypes, zolpidem in vitro binds the receptor preferentially. The receptor is found primarily on the Lamina IV of the sensorimotor cortical regions, substantia nigra (pars reticulata), cerebellum molecular layer, olfactory bulb, ventral thalamic complex, pons, inferior colliculus, and globus pallidus. This selective binding of zolpidem on the receptor is not absolute, but it may explain the relative absence of myorelaxant and anticonvulsant effects in animal studies as well as the preservation of deep sleep (stages 3 and 4) in human studies of zolpidem at hypnotic doses.


Pharmacokinetics
The pharmacokinetic profile of zolpidem Hemitartrate is characterized by rapid absorption from the GI tract and a short elimination half-life (T1/2) in healthy subjects. In a single- dose crossover study in 45 healthy subjects administered 5 and 10 mg Zolpidem Hemitartrate tablets, the mean peak concentrations (Cmax) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/ml, respectively, occurring at a mean time (Tmax) of 1.6 hours for both. The mean Zolpidem Hemitartrate elimination half-life was 2.6 (range: 1.4 to 4.5) and 2.5 (range: 1.4 to 3.8) hours, for the 5 and 10 mg tablets, respectively. Zolpidem Hemitartrate is converted to inactive metabolites that are eliminated primarily by renal excretion. Zolpidem Hemitartrate demonstrated linear kinetics in the dose range of 5 to 20 mg. Total protein binding was found to be 92.5 0.1% and remained constant, independent of concentration between 40 and 790 ng/ml. Zolpidem did not accumulate in young adults following nightly dosing with 20 mg zolpidem Hemitartrate tablets for 2 weeks.


A food-effect study in 30 healthy male volunteers compared the pharmacokinetics of zolpidem Hemitartrate 10 mg when administered while fasting or 20 minutes after a meal. Results demonstrated that with food, mean AUC and Cmax were decreased by 15% and 25% respectively, while mean Tmax was prolonged by 60% (from 1.4 to 2.2 hr). The half-life remained unchanged. These results suggest that, for faster sleep onset, zolpidem Hemitartrate should not be administered with or immediately after a meal.


In the elderly, the dose for Zolpidem Hemitartrate should be 5 mg. This recommendation is based on several studies in which the mean Cmax, T1/2, and AUC were significantly increased when compared to results in young adults. In one study of eight elderly subjects (> 70
years), the means for Cmax, T1/2, and AUC significantly increased by 50% (255 vs 284 ng/ml), 32% (2.2 vs 2.9 hr), and 64% (955 vs 1,562 ng hr/ml), respectively, as compared to younger adults (20 to 40 years) following a single 20 mg oral Zolpidem dose. Zolpidem Hemitartrate did not accumulate in elderly subjects following nightly oral dosing of 10 mg for 1 week.

INDICATIONS

Insomnia
 

DOSAGE AND ADMINISTRATION
Dose - The treatment should always be implemented at the lowest effective dose and maximum dosage never exceeded.
The usual dose for adults is one 10mg tablet daily.
The medicinal product should always be taken just before going to bed.
In elderly subjects or subjects presenting with hepatic insufficiency, dosage should be halved, i.e. 5mg.
Dosage must never exceeded 10mg per day.
In the absence of clinical studies, Zolpidem should not be given to children.
Zolpidem can be prescribed either continuously or on demand, depending on the patient's symptoms.


Treatment duration - The treatment period should be as short as possible, from a few days to four weeks, including the tapering period. The patients should be advised to take the treatment as follows 2 to 5 days for occasional insomnia (e.g. during a trip) 2 to 3 weeks for transient insomnia (e.g. during a troubled period)
Very short treatment periods do not require any gradual treatment discontinuation.
For certain patients, it may be necessary to continue treatment for longer than four weeks, in which case careful and repeated reassessment of the patient's condition is necessary.
 

Mode of Administration

Oral
 

WARNING & PRECAUTIONS
ANAPHYLAXIS (SEVERE ALLERGIC REACTION) AND ANGIOEDEMA (SEVERE FACIAL SWELLING) WHICH CAN OCCUR AS EARLY AS THE FIRST TIME THE PRODUCT IS TAKEN. COMPLEX SLEEP-RELATED BEHAVIORS WHICH MAY INCLUDE SLEEP DRIVING, MAKING PHONE CALLS, PREPARING AND EATING FOOD (WHILE ASLEEP).


The cause of insomnia should be identified wherever possible and the underlying factors treated before a hypnotic is prescribed. The failure of insomnia to remit after a 7-14 day course of treatment may indicate the presence of a primary psychiatric or physical disorder, and the patient should be carefully re-evaluated at regular intervals.
 

1    2    3

Abdomen
Blood
Bone
Breast
Ear

Eye

Face
Hair

Head

Heart
Kidney
Liver
Limbs
Lungs
newMind
Mouth
Muscles
Nails

Neck

newNerves
Nose

Skin

Teeth

Throat

Tongue
 
Health news
 
Cardiovascular Guide
 
Natural Remedies
 
Treatment of Cancer
 
Women's Health
 
Irritable bowel syndrome
 
Common Childhood Illnesses
 
Prescribed Drugs
 
 

     
         
     

 

Disclaimer